Transforming growth factor beta receptor type III (TβRIII or TGFBR3)

Transforming growth factor beta receptor type III (TβRIII, also known as betaglycan) is a transmembrane proteoglycan that functions as a critical co-receptor in TGF-beta signaling and serves as a suppressor of cancer progression, particularly in breast cancer. The receptor modulates ligand binding to the complex formed by type I and type II TGF-beta receptors and is essential for maintaining epithelial cell polarity through proper basolateral membrane localization. Loss or mistargeting of TβRIII expression during cancer development leads to disruption of cell polarity, activation of epithelial-to-mesenchymal transition (EMT), and enhanced cell proliferation, migration, and invasion. The receptor regulates diverse cellular processes including cell proliferation, differentiation, migration, and apoptosis. As a therapeutic target, TβRIII represents an interesting avenue for cancer treatment given its role as a tumor suppressor, though targeting this receptor requires careful consideration of its complex signaling mechanisms and its physiological roles in wound healing and immune regulation.

Other names

Betaglycan

TGF-beta receptor type III functions as a co-receptor and modulator of TGF-beta signaling. It modulates the binding of TGF-beta ligands to the signaling complex formed by type I and type II TGF-beta receptors. While no specific drugs directly targeting TβRIII are listed, general TGF-beta pathway inhibition mechanisms include TGF-beta receptor kinase inhibition (targeting type I receptors in the complex) and TGF-beta ligand neutralization with antibodies.